Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: Association with tumour progression in malignant lipomatous tumours

Journal of Pathology

Volumn 199, Issue 4, 2003, Pages 517-525

  Schneider Stock, Regine ^a   Boltze, Carsten ^a   Jäger, Viola ^a   Epplen, Jörg ^b   Landt, Olfert ^d   Peters, Brigitte ^a   Rys, Janusz ^c   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d NONE

Author keywords

c MYC expression; hTERT expression; Liposarcoma; Telomerase activity

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER; MONOCLONAL ANTIBODY KI 67; MYC PROTEIN; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

CANCER CLASSIFICATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISSECTION; DNA FINGERPRINTING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MOLECULAR PROBE; MYXOSARCOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TISSUE SPECIFICITY; TUMOR GROWTH;

CELL DIVISION; DISEASE PROGRESSION; DNA FINGERPRINTING; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; LIPOSARCOMA; LIPOSARCOMA, MYXOID; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TELOMERE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037388205     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1315     Document Type: Review

References (48)

1. Mentzel T, Fletcher CD. Lipomatous tumours of soft tissue: an update. Virchows Arch 1995; 427: 353-363.
2. Mandahl N, Mertens F, Willen H, Rydholm A, Kreicbergs A, Mitelman F. Nonrandom pattern of telomeric associations in atypical lipomatous tumors with ring and giant marker chromosomes. Cancer Genet Cytogenet 1998; 103: 25-34.
3. DeiTos A, Doglioni C, Piccinin S, Libera DD, Boiocchi M, Fletcher CD. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol 1997; 181: 8-13.
4. Pilotti S, Della TG, Lavarino C, et al. Distinct mdm2/p53 expression pattern in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997; 181: 14-24.
5. Schneider-Stock R, Walter H, Radig K, et al. Mdm2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol 1998; 124: 532.
6. Schneider-Stock R, Walter H, Rys J, Radig K, Hoang-Vu C, Roessner A. No correlation of c-myc overexpression and p53 mutations in liposarcomas. Virchows Arch 1998; 433: 315-321.
7. Schneider-Stock R, Ziegler A, Haeckel C, Franke DS, Rys J, Roessner A. Prognostic relevance of p53 alterations and Mib-1 proliferation index in subgroups of primary liposarcomas. Clin Cancer Res 1999; 5: 2830-2835.
8. Schneider-Stock R, Haeckel C, Radig K, Pein CD, Roessner A. Improved detection of p53 mutations in soft tissue tumors using new gel composition for automated non-radioactive analysis of single-strand conformation polymorphism. Electrophoresis 1997; 18: 2849-2851.
9. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M. Coordinated expression and amplification of the Mdm2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000; 190: 531-536.
10. Yan P, Coindre JM, Benhattar J, Bosman FT, Guillou L. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity. Cancer Res 1999; 59: 3166-3170.
11. Schneider-Stock R, Epplen JT, Walter H, et al. Telomeric lengths and telomerase activity in liposarcomas. Mol Carcinogen 1999; 24: 144-151.
12. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
13. Wen J, Sun L, Zhang M, Zheng MH. Telomerase activation in malignant bone tumors. Mol Diagn 1998; 3: 29-35.
14. Aue G, Muralidhar B, Schwartz HS, Butler MG. Telomerase activity in skeletal sarcomas. Ann Surg Oncol 1998; 5: 627-634.
15. Schneider-Stock R, Rys J, Jäger V, et al. Prognostic significance of telomerase activity in soft tissue sarcomas. Int J Oncol 1999; 15: 775-780.
16. Sangiorgi L, Gobbi GA, Lucarelli E, et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer 2001; 95: 156-161.
17. Bovee JVMG, van den Broek LJCM, Cleton-Jansen AM, Hogendoom PCW. Chondrosarcoma is not characterized by detectable telomerase activity. J Pathol 2001; 193: 354-360.
18. Aogi K, Woodman A, Urquidi V, Mangham DC, Tarin D, Goodison S. Telomerase activity in soft-tissue and bone sarcomas. Clin Cancer Res 2000; 6: 4776-4781.
19. Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A. High telomerase activity and high hTRT mRNA expression differentiate pure myxoid and myxoid/round cell liposarcomas. Int J Cancer 2000; 89: 63-68.
20. De Lange T, DePinho RA. Unlimited mileage from telomerase? Science 1999; 283: 947-949.
21. Blackburn EH. The telomere and telomerase: nucleic acid-protein complexes acting in a telomere homeostasis system: a review. Biochemistry 1997; 62: 1196-1201.
22. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Quelette M. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999; 13: 817-826.
23. Bodnar AG, Quelette M, Frolkis M, Holt SE, Chiu CP, Morin GB. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
24. McChesney PA, Aisner DL, Frank BC, Wright WE, Shay JW. Telomere dynamics in cells with introduced telomerase: a rapid assay for telomerase activity on telomeres. Mol Cell Biol Res Commun 2000; 3: 312-318.
25. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998; 12: 1769-1774.
26. Cerni C. Telomeres, telomerase, and myc: an update. Mutat Res 2000; 462: 31-47.
27. Enzinger FM, Weiss SW (eds). Soft Tissue Tumors (3rd edn). Mosby: St. Louis, 1995.
28. Fletcher CD, Akerman M, Dal Cin P, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors: a report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996; 148: 623-630.
29. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
30. Schneider-Stock R, Emrich T, Peters B, Jaeger V, Roessner A. Analysis of human telomerase reverse transcriptase mRNA (hTERT) expression in myxoid liposarcomas using LightCycler real-time quantitative reverse transcriptase-polymerase chain reaction. Electrophoresis 2001; 22: 1098-1101.
31. Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
32. Epplen JT, Ammer H, Epplen C, et al. Oligonucleotide finger-printing using simple repeat motifs: a convenient, ubiquitously applicable method to detect hypervariability for multiple purposes. EXS 1991; 58: 50-69.
33. Oexle K. Telomere length distribution and Southern blot analysis. J Theor Biol 1998; 190: 369-377.
34. Schneider-Stock R, Epplen C, Radig K, et al. On telomere shortening in soft tissue tumors. J Cancer Res Clin Oncol 1998; 124: 165-171.
35. Abel U. Die Bewertung diagnostischer Tests. Hippokrates-Verlag: Stuttgart, 1993; 141-145.
36. Scheel C, Schaefer KL, Jauch A, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001; 20: 383-344.
37. Yoo J, Robinson RA. Expression of telomerase activity and telomerase RNA in human soft tissue sarcomas. Arch Pathol Lab Med 2000; 124: 393-397.
38. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M. Cloning of human telomerase catalytic subunit (hTERT) gene promotor and identification of proximal core promotor sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
39. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M, Lidereau R. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer 2000; 89: 172-176.
40. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18: 1219-1226.
41. Günes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000; 60: 2116-2121.
42. Kyo S, Takakura M, Tairy T, Kanaya T, Itoh H, Yutsudo M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000; 28: 669-677.
43. Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001; 75: 4467-4472.
44. Hoare SF, Bryce LA, Wisman BA, et al. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERc promotor. Cancer Res 2001; 61: 27-32.
45. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Quellette M. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999; 13: 817-826.
46. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternative splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000; 2: 433-440.
47. Ouellette MM, Aisner DL, Savre-Train I, Wright WE, Shay JW. Telomerase activity does not always imply telomere maintenance. Biochem Biophys Res Commun 1999; 254: 795-803.
48. Reddel RR, Bryan TM, Murnane JP. Immortalized cells with no detectable telomerase activity: a review. Biochemistry 1997; 62: 1254-1262.